Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEND-IT II
NCT07472868Phase 3Recruiting
- Sponsor
- J.W.A. Burger
- Start
- Mar 2026
- Primary completion
- Mar 2030
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of FOLFIRINOX in locally advanced rectal cancer (LARC) (3 arms), sponsored by J.W.A. Burger. Primary endpoint: Pathological Complete Response or Sustained Clinical Complete Response at 1 year. Started Mar 2026; status: recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
locally advanced rectal cancer (LARC)
Beyond the preview
Go deeper on NCT07472868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472868.